Status Awaiting development
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6156

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 October 2024 Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia has now been combined as one appraisal. The ID number to be used for this combined appraisal is ID6232
08 July 2024 This appraisal is now anticipated to begin during early April 2025 when we will write to you about how you can get involved.
31 March 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia have been revised. It is anticipated that the appraisal will begin in mid-May 2024 when we will write to you about how you can get involved.
11 July 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual